Deputy Commissioner of Policy Coordination and Operations
Key decision makers in the same organization
Organization Signals
Public Activity & Signals
Board meetings, strategic plans, and buyer signals from Brian Holstine’s organization
Feb 25, 2026·BoardMeeting
Board
West Virginia Medicaid Drug Utilization Review Board Minutes
The board meeting covered updates from the Pharmaceutical & Therapeutics Committee meeting, including PDL status changes. Prior authorization criteria were approved for Rhapsido, Tonmya, and Hereditary Angioedema agents (both acute and prophylaxis), as well as Vyscoxa. Additionally, the board reviewed fourth-quarter 2025 reports from Gainwell Technologies, the Rational Drug Therapy Program, and Acentra Health, which included overviews of DUR summary reports, prior authorization programs, and RDUR interventions.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
West Virginia Medicaid Drug Utilization Review Board Minutes
The Board meeting included a presentation of pharmaceutical and therapeutics status updates. The Board reviewed and approved numerous prior authorization criteria for various medications, including Wegovy, Qelbree, Paxlovid, Ebglyss, Ubrelvy, Kesimpta, Airsupra, Vraylar, Agamree, and non-factor replacement therapies. Notably, the prior authorization requirement for Hepatitis C treatment was removed. Additionally, the Board reviewed third-quarter 2025 reports from Gainwell Technologies regarding DUR summaries, the Rational Drug Therapy Program, and Acentra Health regarding RDUR interventions.
May 21, 2025·BoardMeeting
Board
West Virginia Medicaid Drug Utilization Review Board Minutes
The board discussed updates from the Pharmaceutical & Therapeutics Committee meeting. Significant focus was placed on reviewing and approving various Prior Authorization Criteria, specifically mandates for drugs including Wegovy, Rezdiffra, and others, often requiring consultation with specialists. Additionally, the board reviewed second-quarter 2025 performance reports from Gainwell Technologies, the Rational Drug Therapy Program, and Acentra Health.
Feb 26, 2025·BoardMeeting
Board
West Virginia Medicaid Drug Utilization Review Board Minutes
The Board received updates regarding the Preferred Drug List status from the Pharmaceutical and Therapeutics Committee meeting. Several proposed prior authorization criteria were reviewed and approved, including criteria for Yorvipath, Dupixent, Alyftrek, Fluticasone HFA, Asmanex HFA, Zurzuvae (as amended), Casgevy, and Lyfgenia. Additionally, the Board reviewed fourth-quarter reports for 2024, including the Gainwell Technologies quarterly report, the Rational Drug Therapy Program summary, and the Acentra Health summary of retrospective DUR interventions.
Extracted from official board minutes, strategic plans, and video transcripts.
